Expression of miR-21 in patients with the acute phase of Kawasaki disease and its clinical significance
JIA Lianhong1, PAN Lulu2, LU Jiacheng1, GENG Zhimin1, WU Rongzhou2, CHU Maoping2.
1.Department of Children’s Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015; 2.Children’s Heart Center, the Second Affiliated Hospital & Yuying Children’s Hospital, Institute of Cardiovascular Development & Translational Medicine, Wenzhou Medical University, Wenzhou, 325027
JIA Lianhong,PAN Lulu,LU Jiacheng, et al. Expression of miR-21 in patients with the acute phase of Kawasaki disease and its clinical significance[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(4): 254-257.
Abstract:Objective: To study the expression of miR-21 in the serum of patients with Kawasaki disease and its clinical significance. Methods: Thirty-three cases of Kawasaki disease and 15 healthy control were collected from the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University in 2014 and 2015. With cel-miR-39 as the external reference gene, the expression of miR-21 was detected with real-time quantitative PCR, and its significance as a marker in diagnosis was evaluated by ROC curve. Results: The expression of miR-21 in serum of KD patients was significantly higher than that in the healthy control group (P<0.05), and return to normal level after treatment. ROC curve indicated miR-21 had a sensitivity of 84.6% and a specificity of 71.4% for distinguishing KD patients from healthy children with an area under the curve (AUC) were 0.736 (95%CI: 0.531~0.941). Further analysis of the clinical pathological features indicated that the level of serum miR-21was associated with PLT. Conclusion: Serum miR-21 level is significantly elevated in KD patients, it may be used as a potential biomarker in diagnosis of KD.
[1] 杜忠东, 梁璐, 孟晓萍, 等. 1995-1999年北京住院小儿川崎病流行病学调查[J]. 中华医学杂志, 2003, 83(21): 38-42.
[2] 张永兰, 杜忠东, 赵地, 等. 2000-2004年北京川崎病住院患儿流行病学调查[J]. 实用儿科临床杂志, 2007, 22(1): 12-15.
[3] YIM D, CURTIS N, CHEUNG M, et al. An update on Kawasaki disease II: clinical features,diagnosis, treatment and outcomes [J]. J Paediatr Child Health, 2013, 49(8): 614-623.
[4] AYUSAWA M, SONOBE T, UEMURA S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)[J]. Pediatr Int, 2005, 47(2): 232-234.
[5] NEWBURGER J W, TAKAHASHI M, GERBER M A, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Pediatrics, 2004, 114(6): 1708-1733.
[6] FISH J E, SANTORO M M, MORTON S U, et al. miR-126 regulates angiogenic signaling and vascular integrity[J]. Dev Cell, 2008, 15(2): 272-284.
[7] MITCHELL P S, PARKIN R K, KROH E M, et al. Circulation microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518.
[8] HUANG Z, HUANG D, NI S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer[J]. Int J Cancer, 2010, 127(1): 118-126.
[9] SHIMIZU C, KIM J, STEPANOWSKY P, et al. Differential expression of miR-145 in children with Kawasaki disease[J]. PloS One, 2013, 8(3): e58159.
[10] YUN K W, LEE J Y, YUN S W, et al, et al. Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease [J]. Pediatr Cardiol, 2014, 35(5): 745-752.
[11] ROWLEY A H, PINK A J, REINDEL R, et al.A study of cardiovascular miRNA biomarkers for Kawasaki disease[J]. Pediatr Infect Dis J, 2014, 33(12): 1296-1299.
[12] NI F F, LI C R, LI Q, et al. Regulatory T cell microRNA expression changes in children with acute Kawasaki disease[J]. Clin Exp Immunol, 2014, 178(2): 384-393.
[13] ZHOU J, WANG K C, WU W, et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation [J]. Proc Natl Acad Sci U S A, 2011, 108(25):10355-10360.
[14] LI Y, YAN L, ZHANG W, et al. MicroRNA-21 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting activator protein-1[J]. Am J Transl Res, 2014, 6(5):507-516.
[15] ZUO K, LI M, ZHANG X, et al. MiR-21 suppresses endothelial progenitor cell proliferation by activating the TGF-beta signaling pathway via downregulation of WWP1[J]. Int J Clin Exp Pathol, 2015, 8(1): 414-422.
[16] RAITOHARJU E, LYYTIKAINEN L P, LEVULA M, et al. miR-21, miR-210, miR-34a, and miR-146ab are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study[J]. Atherosclerosis, 2011, 219(1): 211-217.
[17] WANG M, LI W, CHANG G Q, et al. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities[J]. Arterioscler Thromb Vasc Biol, 2011, 31(9): 2044-2053.
[18] SARKAR J, GOU D, TURAKA P, et al. MicroRNA-21plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration[J]. Am J Physiol Lung Cell Mol Physiol, 2010, 299(6): L861-L871.
[19] JI R, CHENG Y, YUE J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation [J]. Circ Res, 2007, 100(11): 1579-1588.
[20] ROY S, KHANNA S, HUSSAIN S R, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue[J]. Cardiovasc Res, 2009, 82(1): 21-29.
[21] CHENG Y, ZHU P, YANG J, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemiareperfusion injury via anti-apoptosis through its target PDCD4[J]. Cardiovasc Res, 2010, 87(3): 431-439.
[22] 褚茂平, 胡晨, 周爱华, 等. 川崎病血清特异相关miR-23a对人脐静脉内皮细胞生长及迁移的影响[J]. 温州医科大学学报, 2015, 45(5): 321-326.
[23] 褚茂平, 周爱华, 胡晨, 等. miR-130a和miR-125b在川崎病外周血细胞中的表达及意义[J]. 浙江医学, 2015, 37(5):357-362.